Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
QuantumMDx Group Ltd has signed a deal with GlaxoSmithKline to co-develop a quality control analytics system for cell and gene therapies.
SOPHiA GENETICS has scored a CE-IVD mark for its molecular diagnostic device, Solid Tumor Solution (STS).
The US Federal Trade Commission has finally approved Fresenius' $2bn acquisition of NxStage Medical. A complaint filed by the FTC in February 2019 claimed the deal would be anti-competitive.
Device Week, April 10, 2019 – Alcon Is Finally Free From Novartis; EOS Promotes 3D Ortho-Imaging At AAOS
In this edition of Device Week, Catherine Longworth reports on eye-care giant Alcon's $28bn spin-off from Novartis. Marion Webb reviews her interview with executives from EOS imaging SA, a developer of imaging medical devices for orthopedics.
Alcon is going it alone following a spin-out from Swiss pharma giant Novartis. The eye-care device business officially listed on the SIX Stock Exchange on April 9 with a total market capitalization of around $28bn, making it Switzerland's biggest stock deal in a decade.
Israel’s only pediatric and adolescent rehabilitation facility, ALYN Hospital, hopes to pioneer new assistive technologies to help children with special needs. The unique one-stop shop for entrepreneurs is focusing on prototyping and developing rehabilitation solutions that can be brought to an international market.